Urolithin A Nanoparticle Therapy for Cisplatin-Induced Acute Kidney Injury.
Urolithin A Nanoparticle Therapy for Cisplatin-Induced Acute Kidney Injury.
复制标题
尿石素纳米颗粒治疗顺铂引起的急性肾损伤。
作者：
Kumar,MNVRavi
顺铂仍然是一线细胞毒性药物之一。然而，顺铂引起的急性肾损伤(AKI)仍然是一个主要的未得到满足的医疗需求，没有任何批准的药物干预。在顺铂诱导的AKI的发病机制中，活性氧的产生以及炎症和凋亡通路的激活促使了天然抗炎化合物的使用。在这种情况下，使用天然抗氧化剂和抗炎药物如尿素A(UA)来消解炎症可能是有益的。最后，在模型中测试这种组合以消除尿酸刺激肿瘤生长或损害顺铂效力的可能性，可能会被证明对辅助治疗的临床翻译有用。
Cisplatin continues to be one of the frontline cytotoxic drugs. However, cisplatin-induced acute kidney injury (AKI) remains a major unmet medical need without any approved pharmacological interventions. The involvement of reactive oxygen species generation and activation of inflammatory and apoptotic pathways in the pathogenesis of cisplatin-induced AKI prompts the use of natural anti-inflammatory compounds. In this context, resolution of inflammation using natural antioxidant and anti-inflammatory such as urolithin A (UA) could prove beneficial. In the end, testing such combinations in models to eliminate the possibility that UA stimulates tumor growth or compromises the potency of cisplatin could prove useful for clinical translation of adjuvant therapies.